Waratah is a dynamic young biopharmaceutical company founded in April 2000 as a spin-off of RTP Pharma Inc. to develop and commercialize products for its novel, patented therapy – Islet Neogenesis Therapy (I.N.T. ) for the treatment of insulin-dependent diabetes. Diabetes is a disease in which the body does not produce or properly use insulin because of damaged or destroyed insulin producing islet cells. Waratah's I.N.T. research represents a new paradigm in the treatment of diabetes that has the potential to replace insulin injections and diabetes-related transplants. The therapy is based on discoveries in animal models of diabetes which have shown that the systemic administration of certain growth factors stimulates the regeneration of insulin-secreting islet cells in the pancreas. "Islet neogenesis would represent the ultimate in islet replacement (since) such islets reside in their normal home, and (would) not require immuno-protection … of all approaches to islet replacement … islet neogenesis comes nearest to restoring normal pre-diabetic conditions."
Islet Technology, Inc. (ITI) is a biomedical company focused on the processing and purification of insulin-producing islets to be supplied to transplant centers, eventually worldwide. Our core technologies are islet isolation and encapsulation. We are committed to seeing a cure for diabetes happen in our lifetimes. ITI has developed a valuable intellectual property portfolio covering both islet isolation and encapsulation, which we believe will provide the protection needed to effectively commercialize our islet processing services. Islet transplantation is currently in the final phase of human clinical trials begun in the year 2000. For the majority of participants in the trials, the need for externally administered insulin has either been eliminated or greatly reduced, making them insulin self-sufficient. In 2004, it is expected that data from these trials will be submitted to the FDA for approval in order to begin the process of making islet transplants more broadly available. In preparation for commercialization, ITI is in the process of establishing an islet processing center in the Minneapolis/St. Paul area of Minnesota. Once this facility is approved, ITI will be able to supply islets to transplant centers in the U.S. Much work needs to be done in many areas to ensure the availability of islet transplants. Fortunately on the reimbursement front, the recently-passed Medicare Prescription Drug Act established an important precedent by covering islet transplants within clinical trials involving Medicare patients with end stage renal disease. Private insurance companies look to Medicare for leadership in defining new treatments to be covered, so this Medicare study is an important milestone. Islet transplantation will grow as the source of islets expands. ITI expects that islet supply will progress from the current limited supply of deceased donors to include living donors (of partial pancreata), and eventually islets harvested from pigs - a virtually unlimited source. ITI's processing facilities will be able to handle the isolation of islets from all of these sources. When ITI's encapsulation technology is introduced in clinical trials, islets will also be encapsulated at ITI's processing center. Encapsulation involves coating islets with Algi-pure, our proprietary biocompatible material designed to protect islets from attack by the body's immune system. Encapsulation is expected to eliminate or greatly reduce the need for the transplant recipient to take immunosuppressive drugs.
http://www.eiffeltechnologies.com.au
Eiffel Technologies Ltd, is a bioengineering company focused on improving the performance and delivery of pharmaceuticals, proteins and peptides. Based in Melbourne, Australia, the company is dedicated to the development and commercialization of SCF drug technologies to improve therapeutic outcomes and patient administration of new and currently marketed pharmaceuticals. Eiffel Technologies Ltd has international collaborations with Sheffield Pharmaceuticals Inc, Amarin Corporation Plc, Profile Therapeutics Plc and BattellePharma Inc.
Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company is developing a pipeline of products targeted at the therapeutic areas of autoimmune, neutropenia and anemia. On the protein front, Insmed’s product IPLEX is being developed in various stages as a treatment for several medical conditions, with an initial focus on Myotonic Muscular Dystrophy (MMD) and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease) in Italy. Other areas where IPLEX has also shown potential include HIV-associated Adipose Redistribution Syndrome (HARS) and Retinopathy of Prematurity (ROP). IPLEX has United States Food and Drug Administration (FDA) approval. The Company operates an FDA-approved commercial biologics manufacturing facility in Boulder, Colorado. (Source: 10-K)
http://www.transitiontherapeutics.com
Transition Therapeutics Inc. is a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets. The Company operates in one business segment being the research and development of therapeutic agents. The Company has two technologies in development: ELND005 (AZD-103) for the treatment of Alzheimer’s disease, and gastrin analogue, TT-223 for the treatment of diabetes. In June 2007, the Company completed the acquisition of all of the issued and outstanding shares of NeuroMedix Inc. (NeuroMedix). On July 1, 2007, NeuroMedix was amalgamated into Waratah Pharmaceuticals Inc. (Waratah), a wholly-owned subsidiary of the Company. It has three wholly owned subsidiaries: Waratah, Transition Therapeutics Leaseholds Inc. (Leaseholds), and Transition Therapeutics (USA) Inc. (Source: ARS)
Biocon Limited (Biocon) is engaged in manufacturing biotechnological products in the pharmaceutical through fermentation-based technology, and is also engaged in the formulation business. In the biopharmaceuticals segment, it focuses on the manufacture and marketing of active pharmaceutical ingredients that require fermentation and synthetic chemistry capabilities. Its statins portfolio comprises lovastatin, simvastatin, pravastatin and atorvastatin besides other statins under development. Biocon exports simvastatin to the United States, Europe, Japan and Canada; lovastatin to the United States, and pravastatin to the United States and European markets. Biocon produces mycophenolate mofetil, sirolimus and tacrolimus. It develops and markets a mix of specialty and industrial enzymes for a range of industries, including food, beverages, brewing and distilling, textiles and paper. In October 2007, the Company divested its enzymes business to Novozymes A/S. (Source: ARS)
SemBioSys Genetics Inc. is a biotechnology company developing insulin and other protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company’s lead candidate, produced in the plant host safflower, are recombinant human insulin (insulin) to serve the global diabetes market, and apolipoprotein AI and apolipoprotein AI Milano (collectively referred to as Apo AI), a potential next-generation cardiovascular drug. In addition to its pharmaceutical products, the Company is developing a series of non-pharmaceutical products addressing the agricultural biotechnology and nutritional oils markets. Its wholly owned subsidiary, Botaneco Specialty Ingredients Inc., is focused on the commercialization of its first branded line of non-transgenic, oilbody-based ingredients, marketed under the trade name Hydresia, and the development of additional future lines of cosmetic, personal care and prescription topical/dermatology ingredients, which are in the development stage. (Source: ARS)
Generex Biotechnology Corporation is engaged in the research, development and commercialization of drug delivery systems and technologies. The Company focuses on its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. Its wholly owned subsidiaries include Generex Pharmaceuticals Inc., Antigen Express, Inc., Generex (Bermuda), Inc., Generex Pharmaceuticals (USA) LLC and Generex Marketing & Distribution Inc. The Company is in development stage. (Source: 10-K)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory